Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Nitric-oxide synthase, brain | No references | |
Mus musculus | nitric oxide synthase 2, inducible | No references | |
Bos taurus | Nitric-oxide synthase, endothelial | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2407 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2407 | 0.2407 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.7743 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0151 | 0.0151 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0091 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 22.1 nM | Inhibition Assay | BINDINGDB. | No reference |
Ki (binding) | = 1450 nM | Inhibition Assay | BINDINGDB. | No reference |
Ki (binding) | = 2110 nM | Inhibition Assay | BINDINGDB. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.